First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromat... (ents with NF-1 they can create an extrem...)

First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromatosis Study

Date:8/12/2009

ents with NF-1, they can create an extremely negative impact on quality of life by causing pain, disfigurement, and functional impairment. Treatment options for PN are sparse: the only known effective therapy is complete surgical removal; however, this is rarely possible. Although there are other medications being tested for PN, most are not expected to cause tumor shrinkage, but rather to slow or stop tumor growth. In contrast, Aptocine has the potential to shrink the PN tumors and improve the quality of life of patients with this disease.

About Aptocine

Aptocine is a water-soluble drug activated by a small, single-use, disposable drug activator included with the drug. The drug activator contains a tiny array of LEDs at the end of a very narrow (only 1.2 mm wide) flexible coated micro-wire. Administering physicians insert the LED array into a tumor using a biopsy-like procedure and follow with the intravenous injection of Aptocine. When the LEDs activate Aptocine, an energized Aptocine molecule results in the production of singlet oxygen, which can kill target tissues with minimal side effects through vascular closure and apoptosis.

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine for solid tumors as well as other indications. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, as well as in neurofibromatosis, and has clinical or preclinical programs in cardiovascular, ophthalmic, and dermatological diseases.

About the Children's Hospital of Philadelphia and Its Neurofibromatosis Program

The Children's Hospital of Philade
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement
3. Imagenetix, Inc. Reports First Quarter 2010 Results
4. Synthetech Reports First Quarter Fiscal 2010 Results
5. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
6. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
7. Hoya Announces First Quarter Financial Results for FY2010
8. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
10. First genetically engineered malaria vaccine to enter human trials
11. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009

Post Your Comments:

(Date:12/14/2009)... JUPITER, Fla., Dec. 14 Dyadic International, ... it has extended its collaboration with The Scripps ... with Scripps to re-annotate the genome of Dyadic,s ... agreement is a continuation of the successful relationship ... 2006 when Dyadic engaged Scripps to annotate the ...

(Date:12/14/2009)... Mass., Dec. 14 Boston Scientific Corporation (NYSE: ... a public offering of $2 billion aggregate principal amount ... statement. The public offering consists of $850 million ... of 6.00 percent notes due January 2020 and $300 ... Boston Scientific plans to use the net proceeds for ...

(Date:12/14/2009)... Mass., Dec. 14 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that, owing ... atrial fibrillation drug market will increase more than ... billion in 2018 in the United States, France, ... ,, The new Pharmacor report entitled Atrial ...

(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...

Breaking Biology Technology:Dyadic International Extends Collaboration With The Scripps Research Institute 2 Dyadic International Extends Collaboration With The Scripps Research Institute 3 Dyadic International Extends Collaboration With The Scripps Research Institute 4 Dyadic International Extends Collaboration With The Scripps Research Institute 5 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3 The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2 EntreMed Reports Receipt of Third Quarter Royalty Payment 2

[0] Dyadic International Extends Collaboration With The Scripps Research Institute [0] Boston Scientific Announces Completion of $2 Billion Senior Notes Offering [0] The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 [0] EntreMed Reports Receipt of Third Quarter Royalty Payment

... 9 InSet Technologies, an emerging,leader in the ... of medications, announced today the addition of Jon ... from Medtronic Inc. after nearly 30 years of ... including President of the,Neurological Division, President of the ...

... gold awards and one silver award for ... ground-breaking strides in healthcare marketing, WEST CONSHOHOCKEN, Pa., ... agency serving the healthcare,industry, announced today it received two ... nation,s most talented healthcare marketing,professionals for outstanding excellence in ...

... Inc. (Nasdaq:,BIOD) today reported financial results for its second quarter ... $9.6 million or $0.43 per share., "We remain on ... and Chairman of Biodel. "The last patient visits for,both pivotal ... We,expect to announce top line data late in the third ...

InSet Technologies Appoints Jon Tremmel to its Board of Directors Cadient Group Brings Home the Gold at 2008 Aster Awards Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results

(Date:12/13/2009)... LA JOLLA, CADecember 10, 2009Researchers at The Scripps ... how a single protein from an ancient family ... in the body. In addition to providing guidance ... research supplies a theoretical underpinning for the protein,s ... macular degeneration. , The research was published in ...

(Date:12/11/2009)... under stress collectively weigh and initiate different survival strategies ... make strategic decisions that affect their health, wealth and ... published this week in the early online edition of ... Sciences , was accomplished when the scientists applied the ... interplay of genes and proteins that colonies of bacteria ...

(Date:12/11/2009)... discoveries about the deep ocean,s temperature variability and circulation ... , The deep ocean is affected more by surface ... more accurate predictions of factors such as sea level ... temperatures have also been found to result in a ... in a faster transport of large quantities of warm ...

[0] Scripps Research scientists crack mystery of protein's dual function [0] Bacteria provide new insights into human decision making [0] New discoveries could improve climate projections

... growing replacement cartilage offers the first hope of ... by arthritis. The technique, developed at Rice University's ... issue of the journal Tissue Engineering. , "This ... to talk, for the first time, about the ...

... that is used for body growth, is produced in the ... of the National Academy of Sciences. , The researchers -- ... the hippocampus, a structure deep inside the brain that is ... found that more growth hormone is produced in females than ...

... derived from horses, prevent mice infected with H5N1 from ... today in the open access journal Respiratory Research ( ... of horse anti-serum effectively protects infected mice. These results ... be used to prevent death from H5N1 influenza, or ...

Other Biology News:Rice bioengineers pioneer techniques for knee repair 2 Growth hormone is made in the brain, report scientists 2

Rice bioengineers pioneer techniques for knee repair Growth hormone is made in the brain, report scientists Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice

... the industry standard microarray image analysis software ... and analysis tools, visualizations, automation capabilities, performance ... included with every GenePix scanner, and it ... and all types of arrays. A wide ...

... For applications not requiring confocal, the BD ... to the Pathway 435. And, the Pathway ... later applications require it. ... elect to use the laser autofocus, camera ...

... pump, available in a single and twin head, ... design. With the most compact, lightweight package in ... in portable air and gas applications., Available ... T2-01TH). , Delivers 1.5 and 2.0 liters per ...

... Kit containing Vaginal Keratinocyte Progenitors, Rabbit, ... 20% FBS and 10% DMSO at passage ... of optimized medium.This cell culture is supplied ... to provide an additional 6 months of ...

Biology Products:

GenePix Pro from Universal Imaging Corporation (a subsidiary of Molecular Devices)BD Pathway 415 bioimager from BD Biosciences - Bioimaging T2-01 Diaphragm Pump from Parker Hannifin Corporation Vaginal Keratinocyte Progenitors, Rabbit from CHEMICON

First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromat...(ents with NF-1 they can create an extrem...)